A Phase I Clinical Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The main purpose To evaluate the safety and tolerability of pegloticase in subjects with
asymptomatic hyperuricemia by single intravenous infusion at different doses, and to provide
a basis for multiple doses of Pegloticase in subjects with asymptomatic hyperuricemia.
A secondary purpose To evaluate the pharmacokinetics, pharmacodynamics and immunogenicity of
Pegloticase with single-pass intravenous drip in subjects with asymptomatic hyperuricemia.
Exploratory purpose Plasma uricase activity (pUox) analysis of pegloticase with single-pass
intravenous drip in subjects with asymptomatic hyperuricemia.